Ora Pharm Limited 

  Early Stage Capital  

  

  Ora Pharm ltd  

WARNING

The law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors make an informed decision.

If you are an accredited investor under the definition of that term in Rule 501(a) of Regulation D of the US Securities Act of 1933, the usual rules do not apply to offers of financial products made to you. As a result, you may not receive a complete and balanced set of information.

You will also have fewer other legal protections for these investments. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Overview

The opportunity exists for Wholesale Investors to express interest in Ora Pharm Limited (Ora Pharm)


The Company


Ora Pharm is ideally positioned to become the leading New Zealand supplier of high value, pharmaceutical grade medicinal cannabis products to meet rapidly growing international and domestic demand. Ora Pharm is secured a location in North Waikato that is ideally suited to growing cannabis, both indoors (year-round) and outdoors (seasonally). Using specialized greenhouses developed in the US but little-known in the Southern Hemisphere, Ora Pharm is preparing to own the most efficient and productive growing facilities for cannabis in New Zealand.


In a market with very high regulatory barriers to entry and competitors beginning to operate, Ora Pharm stands out as the only company with significant market experience and a strong US market platform to drive growth. Zoe Reece (CEO and Founder) and Stuart Wilcox (Executive Chairman and Head of International Business Development) bring a wealth of experience having previously held senior executive positions at Curaleaf, one of the largest and most respected cannabis corporation in North America with a market capitalisation of over US$11.5 billion.


December 2022 Updates


  • Ora Pharm have their first product being exported in March 2023
  • Firm contracts with a forecast volume of 240kg/month and MOU’s in place for the remaining 140kg/month capacity. This is a value of 18.2m per annum
  • Research is promising coming out of R&D trials which will make Ora Pharm the lowest cost producer out of New Zealand for export quality bulk flower.
  • 2 new board members including Dr Chanda Macias who has built her own vertically integrated multi-state operation in the US and she is the chair of WomenGrow, an organisation which helps females and minorities start businesses in the cannabis industry.


The Offer

Ora Pharm is seeking to raise up to NZ$7.5 million in equity capital through a Series A Funding Round from wholesale and institutional investors. The capital raised will support the expansion of cultivation capacity, develop processing and manufacturing capability and the freehold purchase of land.

For more information please refer to the Information Memorandum in the documents section.

To access further information and be put in contact with the arranger, Register Interest.


Curious about medicinal cannabis?

 

Have you heard about opportunities in medicinal cannabis, but feel hesitant about this emerging industry? Perhaps you’ve invested in early-stage cannabis businesses, but you’d like to understand the sector better?

 

Ora Pharm’s global directors are hosting a series of seminars throughout New Zealand in February and March, bringing you insights and education on the fledgling medicinal cannabis sector. Suitable for investors, medical professionals, public sector officials and media, you’ll learn about:



  • The international medicinal cannabis market, it’s evolution and future forecasts;
  • The global view on New Zealand cannabis products;
  • Opportunities for New Zealand businesses to harness global momentum;
  • The impact of cannabis as a medicine;
  • Medical research and case studies;
  • Investing in cannabis - what you need to know.

 

Ora Pharm’s leadership team are New Zealand’s most experienced medicinal cannabis professionals, with global experts invested in and leading the company's development in Aotearoa. Ora Pharm is the New Zealand medicinal cannabis venture with superior knowledge of global markets, production systems, and go-to-market strategy for finished medical cannabis products internationally.   

 

Ora Pharm are listed on Syndex, with key members of the Board and leadership team available to answer your questions around investment following each seminar.

 

THE SPEAKERS

 

STUART WILCOX |  Executive Chairman, Ora Pharm

 

ZOE REECE |  CEO, Ora Pharm

 

BLAKE SMITH |  Chief Science Officer, Ora Pharm & CEO Zion Pharmaceutical

 

SESSION TIMES

 

Ora Pharm will be hosting seminars in the following locations.

 

AUCKLAND - Tuesday February 28th

WELLINGTON - Wednesday, March 1st

CHRISTCHURCH - Thursday, March 2nd

QUEENSTOWN - Friday, March 3rd

 

For further information please refer to the invitation in the documents tab and to reserve your seat, please email [email protected]

 

To request a private meeting with Ora Pharm’s directors, please email [email protected] or phone Zoe Reece (CEO) on 022 532 5696.

 

For more information on Ora Pharm, visit their website here:  https://orapharm.co.nz/


Issue Type:
Early Stage Capital
Sector:
Health Care
isEOI: true

Investment Details

Investment Type: Wholesale

Wholesale Investment Type: NZ Wholesale Equities

Transaction Size:NZD 7,500,000.00

Committed Capital: 

Pre-money valuation:NZD 25,401,532.00

Minimum Capital Raise:NZD 2,100,000.00

Share Price:NZD 0.00

Unit Price:NZD 3.55

Minimum Investment Size:NZD 50,000.00

Advisor

Bancorp Merchant Bankers

Website:

Email: [email protected]

Phone:+64 27 555 3520

Document Name Description Date Uploaded
Zoom: 0

You do not have any investments to report on.

No trade history available for this issue.

Secondary Market - Ora Pharm Limited Wholesale

No secondary market listings for this issue availble at this time. Check the Exchange for more listings.